Kodiak Sciences Inc. (KOD) Remains Best Positioned After ADVM Setback - Jefferies
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Jefferies analyst Michael Yee reiterated a Buy rating and $190.00 price target on Kodiak Sciences Inc. (NASDAQ: KOD) after Adverum Biotechnologies (NASDAQ: ADVM) announced one DME treated patient had severe inflammation causing blindness in the treated eye and further monitoring of pts - casting increasing doubt on the risk/ benefit for gene therapy in wAMD.
The analyst stated "We think KOD continues to be well positioned as a potl best-in-class VEGF inhibitor with long durability. Primary investor pushback is just a waiting game until Phase III wAMD data reads out in early 2022, perceived unknown risks around safety until everything reads out, and high bar against existing drugs w/ low tolerance for risk by docs, and various debates about pricing, rebating, and other factors over time (docs are very balanced in this respect in all our diligence calls)."
Shares of Kodiak Sciences Inc. closed at $122.21 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Golub Capital BDC (GBDC) at Outperform
- UPDATE: Goldman Sachs Starts Jefferies Group (JEF) at Buy
- WPP Plc (WPP:LN) (WPP) PT Raised to GBP10.70 at HSBC
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!